Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Irinotecan in Previously Untreated Carcinoma of Unknown Primary
NCT00066781Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Feb 2004
- Primary completion
- Apr 2008
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of gemcitabine and irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in carcinoma of unknown primary (CUP) (2 cohorts), sponsored by Cancer and Leukemia Group B. Primary endpoints: Confirmed Response Rate up to 2 years and Adverse Event Profile and Tolerability. Started Feb 2004; status: completed.
02
Drugs
gemcitabineirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
carcinoma of unknown primary (CUP)
Beyond the preview
Go deeper on NCT00066781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00066781.